List of Excipients in Branded Drug MICROGESTIN FE 1/20

Microgestin FE 1/20 Excipient Strategy, Formulation Economics, and Commercial Opportunities

Last updated: September 25, 2026

Microgestin FE 1/20 is a low-dose combined oral contraceptive containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg in 21 active tablets, followed by seven ferrous fumarate tablets. Its excipient profile is conventional, low-cost, and readily reproducible for generic manufacturers. The strongest commercial opportunities are not based on core excipient exclusivity. They are based on improved tablet manufacturability, iron-tablet differentiation, packaging, adherence support, supply reliability, and alternative dosage forms.

The product has limited remaining brand-level patent leverage. Competition is primarily governed by FDA-approved generic equivalents, manufacturing cost, pharmacy substitution, and distribution scale rather than by a durable composition-of-matter or formulation patent estate.

What is Microgestin FE 1/20 and how is it formulated?

Microgestin FE 1/20 is an oral hormonal contraceptive marketed as a 28-day regimen:

Component	Quantity per tablet	Role
Norethindrone acetate	1 mg	Progestin
Ethinyl estradiol	20 mcg	Estrogen
Ferrous fumarate tablets	75 mg per tablet, equivalent to 25 mg elemental iron	Nonhormonal tablets taken during the final seven days

The regimen contains 21 hormonal tablets and seven brown iron-containing tablets. The ferrous fumarate tablets do not provide contraceptive activity. Their primary commercial function is to maintain the daily-tablet routine and reduce confusion during the hormone-free interval. [1]

Microgestin FE 1/20 uses a low-dose estrogen formulation. That creates technical requirements for content uniformity, blend segregation control, assay sensitivity, dissolution performance, and protection against dose variability. The 20-mcg ethinyl estradiol strength is particularly sensitive to manufacturing-process control because the active ingredient represents a very small fraction of total tablet mass.

What excipients are used in Microgestin FE 1/20?

The labeled active tablets use conventional solid-dose excipients, including lactose monohydrate, pregelatinized corn starch, povidone, magnesium stearate, and talc. The ferrous fumarate tablets use a separate excipient system that includes lactose, microcrystalline cellulose, povidone, crospovidone or another disintegrant system, sodium starch glycolate, magnesium stearate, and talc, depending on the marketed presentation and manufacturing source. [1]

The formulation architecture has two distinct parts:

1. A low-dose hormonal tablet requiring blend uniformity and controlled lubrication.
2. A larger iron tablet requiring acceptable hardness, disintegration, color, and swallowability.

The inactive ingredients may differ among approved manufacturers even where the active ingredients, strengths, dosage form, and therapeutic equivalence rating are the same. FDA labeling should be used to confirm the excipient composition of a specific manufacturer and package configuration.

What does each major excipient contribute?

Excipient class	Typical function	Commercial relevance
Lactose monohydrate	Diluent and compressibility aid	Low cost and broad supplier availability
Pregelatinized starch	Binder, disintegrant, and filler	Supports direct compression and tablet robustness
Povidone	Binder	Improves granule strength and content uniformity
Magnesium stearate	Lubricant	Reduces ejection force but can slow dissolution if overused
Talc	Glidant and anti-adherent	Supports powder flow and compression
Microcrystalline cellulose	Filler and dry binder	Helps iron-tablet compression and mechanical strength
Crospovidone or sodium starch glycolate	Superdisintegrant	Controls tablet breakup and dissolution
Iron oxide colorants	Tablet identification	Differentiates iron tablets from active tablets

The critical excipient issue is not whether these materials are novel. It is how the manufacturer combines them with particle-size control, blending time, lubrication time, granulation conditions, compression force, coating, and packaging.

How does the excipient strategy affect manufacturing?

Microgestin FE 1/20 is suitable for conventional wet granulation, dry granulation, or direct-compression development, subject to the active pharmaceutical ingredient's flow and dilution requirements. The low dose of ethinyl estradiol makes direct blending more demanding than a standard high-dose tablet.

Content uniformity and blend segregation

Ethinyl estradiol is present at microgram strength. Manufacturers must manage:

• API particle-size distribution;
• ordered mixing or geometric dilution;
• segregation during transfer and tablet-press feeding;
• sampling representativeness;
• electrostatic charging;
• blend residence time;
• lubricant addition and overmixing.

A supplier that provides engineered excipient grades with consistent particle size, density, and flow can reduce process variability. The commercial value is strongest where the excipient is supported by validated processing data rather than sold as a commodity powder.

Compression and dissolution

Pregelatinized starch, povidone, and microcrystalline cellulose can improve tablet strength. Excessive magnesium stearate or prolonged lubrication can reduce wettability and delay dissolution. This matters because generic manufacturers must demonstrate pharmaceutical equivalence and bioequivalence under FDA requirements.

For the iron tablets, the formulation must balance:

• sufficient hardness for packaging and transport;
• rapid disintegration;
• acceptable mouthfeel and swallowability;
• iron-related taste and odor control;
• stable brown coloration;
• low friability.

Iron salts can create processing and stability challenges, including discoloration, metallic taste, and interaction with moisture-sensitive excipients. These issues create opportunities for coated iron particles, taste-masked iron grades, improved color systems, and lower-dust manufacturing inputs.

What commercial opportunities exist for excipient suppliers?

The largest opportunity is a platform excipient package for low-dose oral contraceptives rather than a single replacement ingredient.

Low-dose hormone tablet platforms

Excipient suppliers can target formulations that improve:

• assay uniformity at 20-mcg ethinyl estradiol;
• low-dose API dispersion;
• tablet weight control;
• compression speed;
• dissolution consistency;
• scale-up from development to commercial production.

Co-processed excipients combining a filler, binder, and disintegrant may reduce formulation development time. However, commercial adoption requires evidence that the formulation performs consistently across multiple API lots and press speeds.

Iron-tablet optimization

The seven ferrous fumarate tablets create a separate opportunity. Manufacturers may seek:

• directly compressible ferrous fumarate;
• lower-density iron granules;
• reduced metallic taste;
• improved color uniformity;
• lower tablet weight;
• enhanced disintegration;
• reduced friability;
• improved moisture stability.

A reformulated iron tablet could improve patient acceptance without changing the contraceptive active tablets. That could support a differentiated generic or a 505(b)(2) product if the change creates a clinically or functionally distinct product and requires a new regulatory strategy.

Packaging and adherence systems

Microgestin FE 1/20 is a calendar-based regimen. Commercial opportunities include:

• blister cards with clearer day-of-week labeling;
• improved child-resistant packaging;
• moisture-barrier packaging;
• unit-dose pharmacy packaging;
• adherence reminders linked to digital packaging;
• color and shape differentiation between active and iron tablets.

Packaging changes can offer practical differentiation without changing the drug formulation. They may also reduce medication errors during the transition from hormonal to iron tablets.

What patents protect Microgestin FE 1/20?

The original product is an older oral contraceptive combination. The active ingredients, norethindrone acetate and ethinyl estradiol, are long-established molecules. The basic combination and conventional tablet excipients generally do not provide a meaningful current exclusivity barrier.

The relevant intellectual-property categories are:

IP category	Relevance to Microgestin FE 1/20
Composition-of-matter patents	Expired for the active ingredients
Basic combination patents	Generally expired or commercially weak
Conventional excipient claims	Difficult to enforce unless narrowly drafted
Specific formulation patents	Possible for modified release, taste masking, or stability
Method-of-use patents	Limited value for established contraceptive use
Packaging and adherence patents	Potentially relevant to differentiated products
Manufacturing-process patents	Possible for low-dose blending or iron-tablet production

The commercial value of a new patent would depend on whether it covers a non-obvious, reproducible formulation that improves a measurable attribute such as dissolution, stability, content uniformity, tolerability, or adherence. A claim covering routine use of lactose, starch, povidone, or magnesium stearate would face significant validity and design-around risks.

What is the FDA regulatory status and Orange Book position?

Microgestin FE 1/20 is an FDA-approved prescription oral contraceptive product. Generic versions are generally pursued through the abbreviated new drug application pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.

For a generic applicant, the main regulatory requirements are:

• pharmaceutical equivalence;
• bioequivalence;
• equivalent strength and dosage form;
• acceptable inactive-ingredient justification;
• manufacturing compliance;
• labeling consistent with the reference product;
• appropriate patent certification.

The Orange Book identifies reference-listed drugs, approved products, therapeutic-equivalence information, and, where applicable, patent and exclusivity information. [2] For an old product such as Microgestin FE 1/20, the primary market barrier is usually regulatory execution and commercial scale rather than active Orange Book exclusivity.

Excipient changes do not automatically require a new clinical efficacy program. They must remain compatible with the ANDA framework and satisfy FDA requirements concerning inactive ingredients, product quality, and bioequivalence. A substantial change in route, dosage form, release profile, or clinical use may move the product outside a conventional ANDA strategy.

When does Microgestin FE 1/20 lose exclusivity?

The practical exclusivity period has already passed. The relevant active ingredients and the conventional oral contraceptive formulation are long off patent, and the product competes with generic norethindrone acetate and ethinyl estradiol tablets with ferrous fumarate.

The key commercial milestones are therefore:

Milestone	Commercial impact
Original approval	Established the reference product
Expiration of early product protection	Opened the market to ANDA competition
Generic approvals	Shifted competition to price and supply
Current period	Differentiation depends on formulation, packaging, adherence, and distribution

Exact patent listings and regulatory status should be verified against the current FDA Orange Book and DailyMed records because listings, sponsors, and marketing status can change. [1,2]

Which companies are challenging or competing with Microgestin FE 1/20?

Competition comes from manufacturers of generic norethindrone acetate and ethinyl estradiol tablets with ferrous fumarate. The market is generally characterized by multiple ANDA holders, private-label distribution, pharmacy benefit substitution, and periodic supply changes.

Competitive factors include:

• wholesale acquisition cost;
• Medicaid and commercial formulary placement;
• pharmacy substitution;
• manufacturing reliability;
• contract manufacturing capacity;
• package configuration;
• reimbursement margins;
• shortage risk;
• ability to maintain consistent supply of ethinyl estradiol and ferrous fumarate.

Paragraph IV litigation is less likely to be a central barrier for this mature product than for a newly approved branded drug. Any Paragraph IV filing, settlement agreement, or patent litigation must be assessed from the current Orange Book, FDA approval records, and federal court dockets rather than inferred from the product's historical patent position.

How strong is the patent estate for an excipient-based Microgestin FE 1/20 product?

A new excipient patent estate would be moderate to weak if it relied on standard excipients in routine proportions. It could become stronger if it covered a defined technical result, such as:

• statistically improved ethinyl estradiol content uniformity;
• a specific co-processed excipient architecture;
• a validated low-dose blending method;
• improved stability under defined humidity conditions;
• taste-masked ferrous fumarate;
• a distinct iron-tablet disintegration profile;
• a protected blister and adherence system;
• a manufacturing process that materially lowers rejection rates.

The best claim strategy would combine composition, process, and performance limitations. A single broad composition claim would be vulnerable to invalidity and design-around arguments.

What generic launch scenarios exist?

Three launch models are commercially realistic.

Commodity generic

The manufacturer uses conventional excipients and competes on price, supply, and pharmacy access. This model has the lowest development cost but the greatest margin pressure.

Differentiated generic

The manufacturer improves tablet robustness, iron-tablet palatability, packaging, or supply reliability. The product remains close enough to the reference product for an ANDA strategy but gains commercial value through lower returns and better adherence.

Reformulated product

The sponsor changes the delivery system, iron component, or regimen and pursues a 505(b)(2) or other appropriate pathway. This model has greater regulatory cost and potential patent value but requires a clear clinical or patient-use advantage.

What manufacturing and geographic IP barriers exist?

There are few inherent geographic barriers to producing the conventional tablets. The main constraints are:

• FDA-compliant manufacturing;
• validated low-dose blending;
• API qualification;
• quality agreements;
• excipient supply continuity;
• inspection readiness;
• serialization and packaging requirements;
• country-specific contraceptive labeling;
• local registration of excipients and colorants.

Patent rights may differ by jurisdiction, but the basic formulation is mature. Geographic commercial barriers are more likely to arise from regulatory registration, local procurement rules, pricing controls, and distribution access than from formulation patents.

Key Takeaways

• Microgestin FE 1/20 contains 21 hormonal tablets and seven ferrous fumarate tablets.
• Its excipient system is conventional and generally available from multiple suppliers.
• The main technical challenge is uniform distribution of 20 mcg of ethinyl estradiol.
• The iron tablets create opportunities for taste masking, lower tablet weight, improved disintegration, and packaging differentiation.
• Core patent protection is not the primary market barrier for this mature product.
• Generic competition is driven by price, supply reliability, therapeutic equivalence, and pharmacy substitution.
• The strongest new IP opportunities involve defined process improvements, performance-based formulation claims, adherence packaging, and differentiated iron-tablet technology.
• Commodity generic entry is straightforward in concept but margin constrained.
• A differentiated product may justify greater regulatory and development investment if it improves tolerability, adherence, or manufacturing yield.

FAQs About Microgestin FE 1/20 Excipient and Commercial Strategy

Can lactose-free Microgestin FE 1/20 be developed?

Yes. Lactose can potentially be replaced with microcrystalline cellulose, mannitol, dibasic calcium phosphate, or a co-processed filler, subject to tablet-performance, stability, and bioequivalence requirements.

Can the ferrous fumarate tablets be removed from the product?

A product without the iron tablets would represent a different presentation and may require a separate regulatory and labeling strategy. The iron tablets are noncontraceptive but preserve the daily dosing sequence.

Is ferrous fumarate necessary for contraceptive efficacy?

No. The ferrous fumarate tablets do not provide contraceptive activity. They are included as nonhormonal tablets in the 28-day regimen.

Can a generic manufacturer use different colorants?

Potentially, but tablet appearance, product identification, labeling, inactive-ingredient acceptability, and medication-error risks must be addressed in the FDA submission.

Could a co-processed excipient create patent protection?

Yes, if the product has a defined composition and demonstrates a non-obvious technical advantage, such as materially improved low-dose content uniformity, dissolution, stability, or manufacturing yield.

References

1. DailyMed. (n.d.). Microgestin FE 1/20: Norethindrone acetate, ethinyl estradiol, and ferrous fumarate tablets prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2015). ANDAs for certain highly purified synthetic peptides: Guidance for industry. FDA.

4. U.S. Food and Drug Administration. (2017). Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. FDA.